Physician profile
Lisa Schalley
NPI 1275683278
$1,782.99
in general payments reported to CMS, 2019-2025
31 companies · $561 in 2025
The $561 reported for 2025 was more than what 79% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $53.73 · 2021: $52.96 · 2022: $142 · 2023: $405 · 2024: $382 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $217.22 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $213.18 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.92 | 2021-2025 | |
| Abbott Laboratories | $187.23 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $115.82 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $81.79 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $80.22 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $63.30 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $55.04 | 2025 | Inspire |
| Novo Nordisk INC | $52.31 | 2019-2025 | Wegovy |
| Verona Pharma, INC. | $50.64 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals Lp | $49.85 | 2023-2025 | Breztri, Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.45 | 2023-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.78 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $45.77 | 2019-2024 | Invega Sustenna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.92 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $28.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $22.03 | 2019 | |
| Pulmonx Corporation | $21.75 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Sanofi Pasteur INC. | $16.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.23 | 2020 | |
| Esperion Therapeutics, INC. | $16.15 | 2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $15.16 | 2025 | Voquezna |
| Astellas Pharma US INC | $14.98 | 2019 | |
| Medtronic, INC. | $14.95 | 2023 | Intellis Adaptivestim |
| Ardelyx, INC. | $14.55 | 2025 | Ibsrela |
| Viiv Healthcare Company | $13.50 | 2023 | Cabenuva |
| Actelion Pharmaceuticals US, INC. | $13.50 | 2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $13.35 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $12.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Schalley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.